- National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece; Inflammation and Autoimmunity Lab, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece
- Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
Volume 35, March 2024, Supplement 1
Sign in to download the Issue in PDF format.
2034733752
Mediterr J Rheumatol 2024;35(Suppl 1):37-44
Article Links
JAK Inhibition as a Potential Treatment Target in Systemic Lupus Erythematosus
Abstract
Janus kinase (JAK)/signal transducers and activators of transcription (STATs) are a group of molecules responsible for signal transduction of multiple cytokines and growth factors in different cell types, involved in the maintenance of immune tolerance. Thus, the dysregulation of this pathway plays a crucial role in the pathogenesis of multiple autoimmune, inflammatory, and allergic diseases and is an attractive treatment target. JAK inhibitors (JAKinibs) have been approved in the treatment of multiple autoimmune diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (SPA). In SLE, there is a plethora of ongoing trials evaluating their efficacy, with tofacitinib, baricitinib and deucravacitinib showing promising results, without major safety concerns. In this review, we will discuss the rationale of targeting JAKinibs in SLE and summarize the clinical data of efficacy and safety of JAKinibs in SLE patients.
Cite this article as: Moysidou G-S, Dara A. JAK Inhibition as a Potential Treatment Target in Systemic Lupus Erythematosus. Mediterr J Rheumatol 2024;35(Suppl 1):37-44.
Article Submitted: 23 Nov 2023; Revised Form: 10 Dec 2023; Article Accepted: 15 Dec 2023; Available Online: 30 Mar 2024
This work is licensed under a Creative Commons Attribution 4.0 International License.
©2024 The Author(s).
